Journal Article

Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement

Domínguez, José, Mandalakas, Anna M, Grobusch, Martin P., Domínguez, Jose, Morel, Florence, Gagneux, Sebastien, Lienhardt, Christian, Grobusch, Martin P, Chesov, Dumitru, Cox, Vivian, van Leth, Frank, Maurer, Florian P, Dudnyk, Andrii, Maurer, Florian, Lange, Christoph, Horsburgh, Charles Robert, Boeree, Martin J, Farhat, Maha R, Kontsevaya, Irina, Mandalakas, Anna Maria, Whitelaw, Andrew, Horsburgh, Charles R, Conradie, Francesca, Gröschel, Matthias I., Guglielmetti, Lorenzo, Molina-Moya, Barbara, Boeree, Martin J., Gröschel, Matthias I, Farhat, Maha R., Miotto, Paolo, Cambau, Emmanuelle, Veziris, Nicolas, Niemann, Stefan, Dheda, Keertan, Merker, Matthias, Lange, Berit

2023

Overview

Drug-resistant tuberculosis is a substantial health-care concern worldwide. Despite culture-based methods being considered the gold standard for drug susceptibility testing, molecular methods provide rapid information about the Mycobacterium tuberculosis mutations associated with resistance to anti-tuberculosis drugs. This consensus document was developed on the basis of a comprehensive literature search, by the TBnet and RESIST-TB networks, about reporting standards for the clinical use of molecular drug susceptibility testing. Review and the search for evidence included hand-searching journals and searching electronic databases. The panel identified studies that linked mutations in genomic regions of M tuberculosis with treatment outcome data. Implementation of molecular testing for the prediction of drug resistance in M tuberculosis is key. Detection of mutations in clinical isolates has implications for the clinical management of patients with multidrug-resistant or rifampicin-resistant tuberculosis, especially in situations when phenotypic drug susceptibility testing is not available. A multidisciplinary team including clinicians, microbiologists, and laboratory scientists reached a consensus on key questions relevant to molecular prediction of drug susceptibility or resistance to M tuberculosis, and their implications for clinical practice. This consensus document should help clinicians in the management of patients with tuberculosis, providing guidance for the design of treatment regimens and optimising outcomes.

• Publisher: Elsevier Ltd,Elsevier Limited
• Subject: Antibiotics / Antitubercular Agents - pharmacology / Antitubercular Agents - therapeutic use / Clinical isolates / Clinical outcomes / Design optimization / Documents / Drug dosages / Drug resistance / Granulomas / Health services / Humans / Infectious diseases / Laboratories / Microbial Sensitivity Tests / Multidrug resistance / Mutation / Mycobacterium tuberculosis / Mycobacterium tuberculosis - genetics / Organisms / Patients / Pharmacodynamics / Reproducibility / Rifampin / Searching / Susceptibility / Tuberculosis / Tuberculosis - drug therapy / Tuberculosis, Multidrug-Resistant - diagnosis / Tuberculosis, Multidrug-Resistant - drug therapy / Tuberculosis, Multidrug-Resistant - microbiology